This month we will be attending the 2024 Maxim Healthcare Virtual Summit. Lipella $LIPO CEO Jonathan Kaufman will be presenting on Thursday, October 17 that 10:30am. Tune in to the live webcast here: m-vest.com/events/healthc… #LIPO #MaximConference #presentation #OLP #investors

.Lipella $LIPO has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform. Read more here: bit.ly/48bWtGK #LIPO #patent #IPprotection #liposomes #drugdelivery

We are pleased to announce we will be attending the 2024 Spartan Capital Investor Conference in New York that will be held on November 4th, 2024. Lipella $LIPO CEO Jonathan Kaufman will be presenting at 9:25am EST and is available for one-on-one meetings with registered

Our recent patent news has been featured by BioTuesdays . “We believe our proprietary liposomal delivery platform holds significant potential to enhance efficacy and tolerability across various therapeutic areas, including oncology, cancer survivorship and immunotherapy,” stated

Today $LIPO has announced the completion of dosing for the first cohort in our multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP). The pace of our promising progress puts us on track to

.Lipella (Nasdaq: $LIPO) has announced a publication in Cureus, a peer-reviewed article highlighting the potential treatment for Oral Lichen Planus (OLP) with a focus on localized drug delivery. The paper emphasizes the potential of Lipella’s investigational

.Lipella is pleased to announce the FDA has granted approval for Expanded Access Program for LP-310 in Oral Lichen Planus (OLP). This program will allow OLP patients to access treatments outside of a clinical trial that are not yet approved by the FDA and reinforces

.Lipella $LIPO is pleased to announce significant Phase 2a Topline Data for LP-310, our liposomal-tacrolimus oral rinse formulation of LP-10, to treat oral lichen planus (OLP). LP-310 demonstrated clinically meaningful reductions in pain, ulceration, and inflammation

.Lipella $LIPO is pleased to announce the completion of patient enrollment for its Phase 2a study of LP-310 for Oral Lichen Planus. Topline results are expected in Q2 2025. With the final cohort now fully enrolled we are eager to share the data and shape our next steps.

IN CASE YOU MISSED IT: Our co-founder Michael Chancellor was featured on the Pharmaverse Podcast where he provides insights into his work with Lipella and leadership advice to those in the field. #stockstowatch #stocksinnews #investors #smallcaps linkedin.com/posts/activity…

.Lipella $LIPO recent Phase 2a Trial news was featured by Clinical Trials Arena. Read more here: clinicaltrialsarena.com/news/lipella-o… #stockstowatch #stocksinnews #investors #smallcaps

Lipella announces additional positive Phase 2a data for LP-310 in oral lichen planus. The 0.50 mg cohort showed statistically significant improvements across key clinical measures with no treatment-related serious adverse events. Final results from the 1.0 mg cohort expected Q2

We are pleased to announce that our LP-10 abstract on oral lichen planus has been accepted for podium presentation at the 2025 AAOM/EAOM International Meeting in Las Vegas. The presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute, a member of Lipella’s

.Lipella is proud to present Phase 2a data for LP-310 in Oral Lichen Planus at the 2025 AAOM/EAOM International Meeting. The topline results from the 0.25 mg and 0.50 mg dose cohorts highlight statistically significant safety and efficacy outcomes in this underserved

.Lipella $LIPO Pharmaceuticals has announced the renewal of its manufacturing collaboration agreement with Cook MyoSite, Inc. This CMC collaboration is increasingly valuable to Lipella as the clinical pipeline matures toward commercializing assets. Read more here: